Zhonghua Nei Ke Za Zhi. 2020 Nov 1;59(11):847-853. doi: 10.3760/cma.j.cn112138-20200306-00202.
The outbreak of corona virus disease 2019 (COVID-19) has spread to more than 70 countries worldwide and there was a higher mortality in those who developed serious illness.Cytokine storm syndrome is an important pathophysiological basis for COVID-19 patients developing into severe or critical conditions. It was indicated in the diagnosis and treatment scheme, by the National Health Commission of the People's Republic of China, that blood purifications such as plasma exchange, plasma adsorption, hemoperfusion, hemofiltration and plasmafiltration could be considered for use in the critical patients with cytokine storm syndrome. This expert consensus, proposed by the Chinese Society of Nephrology and the Nephrology Committee of Chinese Research Hospital Association, is to guide and standardize the clinical application of blood purifications in the treatment of severe or critical patients with COVID-19.
2019年冠状病毒病（COVID-19）疫情已蔓延至全球70多个国家，病情严重者死亡率更高。细胞因子风暴综合征是COVID-19患者发展为重症或危重症的重要病理生理基础。中华人民共和国国家卫生健康委员会在诊疗方案中指出，对于出现细胞因子风暴综合征的危重症患者，可考虑采用血浆置换、血浆吸附、血液灌流、血液滤过和血浆滤过等血液净化治疗。本专家共识由中国肾脏病学会和中国研究型医院学会肾脏病专业委员会提出，旨在指导和规范血液净化在COVID-19重症或危重症患者治疗中的临床应用。
